A Phase 1 interventional study of tofacitinib and tofacitinib in Psoriasis and Immunomodulation, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-02-20.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.
Among the 19 studies testing tofacitinib in Psoriasis, this one is the 16th largest by enrollment, is the only one that started in 2002, is one of 2 in phase 1, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Lahore General Hospital · Sites in Pakistan
Ages 18–70 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Pak Emirates Military Hospital
Ages 18–70
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 135 across the 19 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
57 studies in Psoriasis by Pfizer: none open now, none under way, none of them phase 3. Of 56 finished, 46 (82%) have results posted.
Among the 57 studies in Psoriasis by Pfizer, this one is the 32nd largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2002, is one of 10 in phase 1, and was the 42nd registered.
Pfizer’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing tofacitinib in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581418Pak Emirates Military HospitalComparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tofacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 57 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg BID for 13 days and once on Day 14
Drug: tofacitinib
10 mg BID for13 days and once on Day 14\*
Drug: tofacitinib
20 mg BID for 13 days and once on Day 14
Drug: tofacitinib
30 mg BID for 13 days and once on Day 14
Drug: tofacitinib
60 mg QD for 14 days
Drug: tofacitinib
50 mg BID x 13 days and once on day 14
Drug: tofacitinib
5 mg BID For 13 days and once on Day 14
10 mg BID for 13 days and once on Day 14\*
20 mg BID for 13 days and once on Day 14
30 mg BID for 13 days and once on Day 14
60 mg tablet once a day (QD) for 14 days
50 mg tablets two times a day (BID) for 13 days and once on day 14
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo.
Time frame: 8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1
Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0.
Time frame: Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Time frame: 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14
Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.
Time frame: 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21
Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc \>=500 msec were reported.
Time frame: 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1
AUCtau = area under the curve from time zero to end of dosing interval.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14
AUCtau = area under the curve from time zero to end of dosing interval.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Maximum Observed Plasma Concentration (Cmax) at Day 1
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Maximum Observed Plasma Concentration (Cmax) at Day 14
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Accumulation Ratio (R0)
Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, 1 hr post-dose on Day 1
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, hr 0 on Day 2
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, hr 0 on Day 4
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, hr 0 on Day 7
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, hr 0 on Day 10
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline; hr 0, 8 hr post-dose on Day 14
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, Hour 0 on Day 18
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, hr 0 on Day 21
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, hr 0 on Day 28
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
Time frame: Baseline, hr 0 on Day 42
Change From Baseline in Immune Cell Function at Day 14
The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (\<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, \>= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy.
Time frame: Baseline (Within 7 days prior to Day 1), Day 14
Change From Baseline in Reticulocyte Count at Day 2
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 2
Change From Baseline in Reticulocyte Count at Day 4
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 4
Change From Baseline in Reticulocyte Count at Day 7
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 7
Change From Baseline in Reticulocyte Count at Day 10
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 10
Change From Baseline in Reticulocyte Count at Day 15
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 15
Change From Baseline in Reticulocyte Count at Day 21
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 21
Change From Baseline in Reticulocyte Count at Day 28
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 28
Change From Baseline in Reticulocyte Count at Day 42
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
Time frame: Baseline (Within 7 days prior to Day 1), Day 42
Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function
Time frame: Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42
Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)
EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured.
Time frame: Day 14
Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14
Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity.
Time frame: Baseline (Within 7 days prior to Day 1) up to Day 14
Number of Participants With Physician's Global Assessment (PGA) of Psoriasis
Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis).
Time frame: Baseline (Within 7 days prior to Day 1) up to Day 14
Gene Expression in Psoriatic Plaque Biopsies
Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC.
Time frame: Day 14
Immunohistochemistry From Psoriatic Plaque Biopsies
Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo.
Time frame: Baseline (within 7 days prior to Day 1), Day 14
Number of Participants With Keratin 16 (K16) Expression
Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes.
Time frame: Baseline (within 7 days prior to Day 1) up to Day 14
Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression
Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes.
Time frame: Baseline (within 7 days prior to Day 1) up to Day 14
Gene Expression in Peripheral Blood
Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 \[SF5\]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA).
Time frame: Day 14
| Milestone | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 10 | 9 | 9 | 8 | 13 |
| Completed | 5 | 5 | 9 | 9 | 9 | 8 | 13 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| millisecond (msec) | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline for HPD 1 | 372.20 ± 34.3 | 348.47 ± 23.52 | 369.40 ± 19.47 | 375.74 ± 24.65 | 383.96 ± 18.10 | 371.29 ± 28.33 | 370.95 ± 18.00 |
| Change at HPD 1 on Day 1 | -6.33 ± 25.91 | 15.73 ± 9.04 | -6.33 ± 21.67 | 2.70 ± 14.54 | 1.63 ± 14.09 | -2.79 ± 13.28 | -4.21 ± 12.61 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline for HPD 2 | 369.67 ± 33.78 | 350.27 ± 20.76 | 372.87 ± 21.10 | 377.48 ± 24.26 | 387.00 ± 18.81 | 374.00 ± 26.75 | 369.87 ± 17.53 |
| Change at HPD 2 on Day 1 | -0.40 ± 26.39 | 9.80 ± 13.71 | -6.90 ± 22.22 | -0.15 ± 12.82 | -0.07 ± 9.40 | -1.58 ± 13.66 | -2.05 ± 16.76 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline for HPD 4 (n=5,5,10,9,9,8,13) | 373.73 ± 31.71 | 348.07 ± 23.34 | 373.20 ± 21.78 | 373.15 ± 20.46 | 381.44 ± 20.02 | 381.17 ± 26.96 | 368.00 ± 18.04 |
| Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13) | -4.53 ± 23.17 | 11.53 ± 12.32 | 2.19 ± 20.98 | 2.96 ± 17.94 | 7.74 ± 14.69 | -8.17 ± 14.32 | -2.82 ± 10.82 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline for HPD 8 (n=5,5,10,9,9,8,13) | 364.13 ± 36.00 | 356.73 ± 25.62 | 366.90 ± 22.02 | 374.56 ± 22.73 | 378.15 ± 23.91 | 372.25 ± 28.29 | 367.56 ± 17.95 |
| Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13) | -1.27 ± 15.93 | -6.60 ± 10.71 | -3.96 ± 18.54 | -3.44 ± 12.75 | 7.67 ± 16.08 | -9.83 ± 15.12 | -9.03 ± 11.52 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline for HPD 12 (n=5,5,10,9,9,8,13) | 371.73 ± 31.50 | 351.27 ± 22.90 | 372.63 ± 22.54 | 370.11 ± 25.70 | 379.78 ± 24.93 | 363.08 ± 31.21 | 361.54 ± 16.29 |
| Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13) | -6.27 ± 19.05 | -2.60 ± 5.27 | -4.15 ± 17.90 | 0.15 ± 9.79 | -3.22 ± 19.73 | -2.88 ± 14.01 | -1.36 ± 13.60 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo.
| msec | CP-690,550 60 mg (Cohort 5) | Placebo |
|---|---|---|
| Baseline for HPD 16 | 377.15 ± 19.50 | 345.44 ± 18.77 |
| Change at HPD 16 on Day 1 | 11.19 ± 19.98 | 13.11 ± 7.26 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline for HPD 0 | 374.80 ± 28.95 | 360.40 ± 28.03 | 367.70 ± 30.28 | 372.81 ± 27.83 | 383.41 ± 19.25 | 367.50 ± 22.12 | 364.03 ± 20.96 |
| Change at HPD 0 on Day 14 | -14.53 ± 11.39 | 11.00 ± 12.00 | -0.33 ± 14.08 | 7.22 ± 16.38 | -9.70 ± 13.15 | -0.79 ± 17.48 | -7.08 ± 16.21 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14 | -8.87 ± 12.12 | 22.27 ± 13.72 | 0.11 ± 12.55 | 2.81 ± 15.98 | -0.96 ± 14.63 | 0.71 ± 20.43 | -12.87 ± 17.82 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14 | -3.80 ± 12.18 | 18.67 ± 11.15 | -3.93 ± 13.21 | 6.89 ± 13.98 | -3.81 ± 17.18 | 2.46 ± 22.04 | -12.28 ± 19.35 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14 | -13.80 ± 15.37 | 6.53 ± 7.81 | -8.41 ± 7.25 | 18.96 ± 18.55 | 9.59 ± 10.70 | -4.79 ± 21.58 | -8.46 ± 21.09 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14 | -9.33 ± 11.31 | -0.53 ± 9.83 | -6.15 ± 15.86 | -1.96 ± 13.75 | 4.85 ± 18.51 | -2.67 ± 23.28 | -12.36 ± 11.38 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
| msec | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14 | -13.47 ± 12.76 | 8.00 ± 8.48 | -10.52 ± 10.63 | 0.81 ± 13.99 | -7.44 ± 22.73 | -0.63 ± 23.46 | -4.82 ± 15.31 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.
| participants | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| QTcB,Maximum increase from baseline:30 to <60msec | 0 | 1 | 2 | 1 | 3 | 2 | 5 |
| QTcB,Maximum increase from baseline:>=60msec | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| QTcF,Maximum increase from baseline:30 to <60msec | 0 | 1 | 0 | 1 | 3 | 0 | 1 |
| QTcF,Maximum increase from baseline:>=60msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc \>=500 msec were reported.
| participants | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| QTcB | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUCtau = area under the curve from time zero to end of dosing interval.
| nanogram*hour/milliliter (ng*hr/mL) | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) |
|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1 | 161 ± 86.1 | 349 ± 34.7 | 732 ± 232 | 860 ± 235 | 2120 ± 837 | 1720 ± 453 |
AUCtau = area under the curve from time zero to end of dosing interval.
| ng*hr/mL | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) |
|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14 | 154 ± 80.3 | 422 ± 49.5 | 850 ± 216 | 1350 ± 308 | 2600 ± 1580 | 1780 ± 501 |
| nanogram/milliliter (ng/mL) | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) at Day 1 | 48.3 ± 24.5 | 90.5 ± 20.4 | 212 ± 62.3 | 180 ± 53.1 | 457 ± 88.2 | 429 ± 99.1 |
| ng/mL | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) at Day 14 | 50.9 ± 21.2 | 87.7 ± 13.2 | 194 ± 53.9 | 225 ± 43.9 | 568 ± 205 | 403 ± 133 |
| hr | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) |
|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1 | 0.50 (0.25 to 1.00) | 0.50 (0.50 to 1.00) | 0.50 (0.25 to 2.00) | 0.50 (0.50 to 3.00) | 1.00 (0.50 to 3.00) | 1.00 (0.50 to 2.00) |
| hr | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) |
|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14 | 0.50 (0.50 to 0.50) | 1.00 (0.50 to 1.00) | 0.50 (0.25 to 2.00) | 1.00 (0.50 to 4.00) | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 2.00) |
Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1.
| Ratio | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) |
|---|---|---|---|---|---|---|
| Accumulation Ratio (R0) | 0.974 ± 0.181 | 1.22 ± 0.203 | 1.22 ± 0.389 | 1.62 ± 0.343 | 1.16 ± 0.270 | 1.14 ± 0.176 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 1: CD3 | -14.39 ± 14.6 | 12.02 ± 18.2 | 1.17 ± 17.7 | 12.44 ± 17.4 | 8.38 ± 23.9 | 12.83 ± 14.0 | 0.52 ± 16.5 |
| Change at Day 1: CD4 | -18.48 ± 19.4 | 8.65 ± 23.5 | -4.29 ± 15.2 | 5.99 ± 15.6 | -1.13 ± 19.9 | 8.54 ± 10.7 | 1.35 ± 18.3 |
| Change at Day 1: CD8 | -7.58 ± 11.0 | 26.05 ± 25.1 | 8.90 ± 22.1 | 18.34 ± 21.4 | 13.90 ± 21.9 | 25.44 ± 14.6 | 0.42 ± 16.5 |
| Change at Day 1: CD16/56 | 11.22 ± 27.0 | 79.99 ± 33.7 | 81.44 ± 62.7 | 74.07 ± 38.6 | 104.44 ± 85.8 | 103.74 ± 21.2 | -9.72 ± 18.3 |
| Change at Day 1: CD19 | -27.11 ± 16.7 | -4.02 ± 30.9 | -10.30 ± 18.1 | -8.23 ± 10.4 | -6.22 ± 29.9 | -0.66 ± 9.0 | -6.46 ± 22.4 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 2: CD3 | 8.88 ± 24.0 | 34.74 ± 27.4 | 23.93 ± 31.1 | 46.07 ± 31.4 | 14.05 ± 24.4 | 52.43 ± 34.3 | -5.18 ± 17.4 |
| Change at Day 2: CD4 | 8.58 ± 26.7 | 33.29 ± 25.4 | 26.73 ± 31.9 | 44.17 ± 33.9 | 18.85 ± 34.9 | 55.80 ± 35.5 | -6.85 ± 18.0 |
| Change at Day 2: CD8 | 12.67 ± 19.3 | 32.68 ± 30.1 | 19.68 ± 29.3 | 43.04 ± 29.1 | 16.96 ± 25.1 | 50.97 ± 30.4 | -4.17 ± 20.2 |
| Change at Day 2: CD16/56 | 18.27 ± 30.4 | 61.26 ± 47.8 | 52.84 ± 54.8 | 63.21 ± 45.1 | 0.61 ± 37.7 | 103.79 ± 45.8 | 5.61 ± 35.7 |
| Change at Day 2: CD19 | 7.58 ± 40.3 | 9.56 ± 30.5 | 17.40 ± 24.5 | 30.39 ± 11.3 | 7.04 ± 33.5 | 45.72 ± 44.4 | -4.22 ± 24.4 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 4: CD3 | -15.29 ± 21.1 | 51.71 ± 31.4 | 29.11 ± 49.0 | 71.55 ± 44.5 | 34.28 ± 41.8 | 32.81 ± 28.0 | 3.80 ± 28.2 |
| Change at Day 4: CD4 | -15.87 ± 22.4 | 43.87 ± 22.0 | 30.90 ± 51.7 | 72.02 ± 43.1 | 42.50 ± 56.7 | 39.46 ± 27.2 | 6.08 ± 31.3 |
| Change at Day 4: CD8 | -10.94 ± 17.8 | 56.72 ± 43.5 | 18.18 ± 41.7 | 61.61 ± 41.4 | 31.95 ± 32.6 | 29.81 ± 33.5 | -0.31 ± 24.8 |
| Change at Day 4: CD16/56 | -23.08 ± 22.5 | 90.73 ± 41.6 | 10.67 ± 44.3 | 24.27 ± 55.5 | -5.23 ± 43.2 | -1.66 ± 44.8 | 7.18 ± 59.8 |
| Change at Day 4: CD19 | -12.59 ± 27.2 | 41.44 ± 18.2 | 53.84 ± 71.8 | 56.27 ± 35.1 | 44.76 ± 55.7 | 77.25 ± 50.7 | -2.55 ± 37.5 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 7: CD3 | 5.72 ± 20.6 | 28.15 ± 26.0 | 13.47 ± 55.4 | 25.51 ± 38.9 | 1.61 ± 26.0 | 34.77 ± 33.1 | -3.08 ± 17.3 |
| Change at Day 7: CD4 | 6.52 ± 22.6 | 29.39 ± 22.2 | 14.99 ± 56.6 | 24.48 ± 39.3 | 0.91 ± 26.6 | 37.42 ± 33.1 | -3.28 ± 17.8 |
| Change at Day 7: CD8 | 6.76 ± 18.5 | 31.50 ± 42.3 | 7.21 ± 50.1 | 21.74 ± 37.5 | 1.74 ± 25.2 | 30.95 ± 27.8 | -3.10 ± 19.8 |
| Change at Day 7: CD16/56 | -10.57 ± 14.3 | 29.97 ± 56.6 | 17.02 ± 83.0 | -1.43 ± 40.0 | -2.37 ± 56.4 | -7.95 ± 30.2 | 2.26 ± 35.2 |
| Change at Day 7: CD19 | 13.01 ± 36.3 | 34.47 ± 24.6 | 55.54 ± 83.2 | 72.86 ± 67.4 | 15.14 ± 46.0 | 98.64 ± 102.9 | -2.40 ± 22.3 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 10: CD3 | 5.70 ± 18.9 | 8.76 ± 35.7 | 12.47 ± 49.1 | 36.76 ± 43.8 | 11.30 ± 50.0 | 12.61 ± 30.6 | -3.69 ± 27.9 |
| Change at Day 10: CD4 | 6.86 ± 20.9 | 16.87 ± 34.0 | 14.50 ± 50.8 | 38.22 ± 43.0 | 14.61 ± 54.4 | 16.85 ± 32.4 | -4.52 ± 27.5 |
| Change at Day 10: CD8 | 5.34 ± 20.9 | 4.13 ± 39.8 | 0.68 ± 35.4 | 28.77 ± 40.5 | 16.81 ± 62.4 | 7.87 ± 20.1 | -4.14 ± 30.6 |
| Change at Day 10: CD16/56 | -16.73 ± 29.3 | -25.53 ± 41.4 | -16.22 ± 22.8 | -33.38 ± 27.2 | -21.99 ± 36.1 | -37.90 ± 24.8 | -10.82 ± 31.3 |
| Change at Day 10: CD19 | 24.06 ± 26.9 | 34.97 ± 38.7 | 76.05 ± 71.1 | 79.94 ± 69.2 | 63.64 ± 180.0 | 84.57 ± 109.7 | -13.19 ± 31.5 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at 0 hr post dose on Day 14: CD3 | 1.01 ± 16.0 | 26.93 ± 21.5 | 7.07 ± 33.0 | 14.91 ± 32.1 | 10.74 ± 37.1 | 12.69 ± 43.9 | -15.05 ± 21.7 |
| Change at 8 hr post dose on Day 14: CD3 | 7.98 ± 18.2 | 76.59 ± 28.7 | 19.79 ± 23.1 | 40.85 ± 36.7 | 44.08 ± 61.6 | 15.64 ± 32.3 | -7.20 ± 20.7 |
| Change at 0 hr post dose on Day 14: CD4 | -1.91 ± 19.0 | 31.80 ± 11.0 | 9.86 ± 41.2 | 14.80 ± 32.3 | 9.67 ± 49.1 | 17.69 ± 46.8 | -15.51 ± 25.1 |
| Change at 8 hr post dose on Day 14: CD4 | 7.31 ± 18.0 | 86.33 ± 30.3 | 22.68 ± 24.8 | 38.65 ± 36.7 | 57.94 ± 91.5 | 19.21 ± 30.4 | -5.88 ± 23.1 |
| Change at 0 hr post dose on Day 14: CD8 | 6.92 ± 9.1 | 25.57 ± 37.0 | -3.36 ± 23.6 | 10.68 ± 30.9 | 17.58 ± 42.4 | 9.89 ± 35.5 | -14.21 ± 20.2 |
| Change at 8 hr post dose on Day 14: CD8 | 10.36 ± 17.3 | 70.26 ± 34.0 | 16.37 ± 16.9 | 40.38 ± 34.4 | 42.59 ± 59.2 | 31.87 ± 86.9 | -6.94 ± 18.9 |
| Change at 0 hr post dose on Day 14: CD16/56 | -0.34 ± 25.0 | 1.73 ± 52.8 | -28.06 ± 32.3 | -43.06 ± 21.4 | -20.03 ± 44.6 | -42.70 ± 35.0 | -6.49 ± 25.4 |
| Change at 8 hr post dose on Day 14: CD16/56 | -8.06 ± 19.7 | 41.85 ± 47.4 | -6.44 ± 38.0 | -8.75 ± 46.5 | 45.94 ± 114.4 | -14.38 ± 37.9 | -4.09 ± 34.0 |
| Change at 0 hr post dose on Day 14: CD19 | 16.76 ± 25.1 | 39.97 ± 33.3 | 69.43 ± 75.9 | 68.14 ± 72.2 | 60.99 ± 151.4 | 116.93 ± 215.8 | -16.04 ± 33.1 |
| Change at 8 hr post dose on Day 14: CD19 | 20.74 ± 19.8 | 92.47 ± 47.9 | 117.56 ± 52.4 | 95.87 ± 86.6 | 78.60 ± 94.0 | 152.66 ± 263.6 | 2.53 ± 36.2 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 18: CD3 | 13.89 ± 27.9 | -14.04 ± 30.6 | -10.24 ± 21.3 | -10.65 ± 18.5 | -14.54 ± 13.5 | -46.69 ± 17.5 | 3.91 ± 20.0 |
| Change at Day 18: CD4 | 12.44 ± 29.6 | -13.35 ± 24.9 | -7.80 ± 21.5 | -8.89 ± 17.4 | -13.66 ± 19.1 | -42.60 ± 18.8 | 7.17 ± 17.1 |
| Change at Day 18: CD8 | 17.52 ± 32.7 | -9.18 ± 44.1 | -12.38 ± 23.1 | -18.76 ± 24.0 | -13.47 ± 8.0 | -51.68 ± 18.1 | 4.70 ± 15.9 |
| Change at Day 18: CD16/56 | 11.58 ± 31.5 | -7.64 ± 73.7 | -21.03 ± 46.0 | -48.63 ± 63.5 | -17.13 ± 45.7 | -76.21 ± 28.2 | -0.68 ± 22.4 |
| Change at Day 18: CD19 | 16.98 ± 50.8 | -15.78 ± 15.9 | 13.95 ± 32.5 | 22.65 ± 45.8 | -8.14 ± 35.6 | -29.44 ± 25.4 | -4.67 ± 25.8 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 21: CD3 | -25.48 ± 10.5 | -6.38 ± 14.8 | -42.27 ± 23.9 | -14.82 ± 20.2 | -7.93 ± 13.5 | -27.37 ± 13.3 | -1.12 ± 17.8 |
| Change at Day 21: CD4 | -29.75 ± 9.6 | -2.88 ± 7.4 | -41.01 ± 24.4 | -11.01 ± 20.7 | -9.41 ± 16.5 | -22.38 ± 13.1 | 1.16 ± 19.8 |
| Change at Day 21: CD8 | -19.51 ± 14.0 | -6.00 ± 31.1 | -43.55 ± 28.9 | -23.78 ± 21.1 | -2.12 ± 14.8 | -32.49 ± 15.6 | -4.01 ± 17.8 |
| Change at Day 21: CD16/56 | -7.23 ± 23.5 | -9.21 ± 63.8 | -47.87 ± 30.7 | -48.04 ± 19.0 | 5.62 ± 35.4 | -66.94 ± 19.2 | -2.22 ± 44.1 |
| Change at Day 21: CD19 | -20.90 ± 25.4 | -14.61 ± 26.7 | -22.60 ± 26.6 | -7.67 ± 34.8 | -17.50 ± 27.7 | -12.51 ± 22.9 | 0.98 ± 24.3 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 28: CD3 | -18.11 ± 10.0 | 9.29 ± 24.5 | 0.38 ± 34.1 | -4.60 ± 17.9 | -7.60 ± 23.3 | -22.08 ± 9.7 | -2.57 ± 25.0 |
| Change at Day 28: CD4 | -21.29 ± 13.3 | 10.97 ± 29.8 | 1.02 ± 35.2 | -5.90 ± 15.7 | -11.51 ± 19.8 | -19.90 ± 6.3 | -2.86 ± 24.9 |
| Change at Day 28: CD8 | -11.96 ± 9.0 | 11.58 ± 18.8 | -2.84 ± 35.0 | -9.33 ± 18.5 | -6.13 ± 21.8 | -23.56 ± 13.7 | -1.56 ± 26.7 |
| Change at Day 28: CD16/56 | 5.13 ± 35.9 | 21.93 ± 51.3 | -10.27 ± 31.2 | -28.52 ± 51.6 | 11.21 ± 55.9 | -26.96 ± 39.4 | 13.32 ± 50.8 |
| Change at Day 28: CD19 | -7.96 ± 24.3 | 21.29 ± 23.5 | 1.96 ± 42.3 | -6.53 ± 21.8 | -16.50 ± 28.3 | -11.58 ± 22.1 | -12.51 ± 19.1 |
Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.
| percent change | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change at Day 42: CD3 | -20.79 ± 29.0 | -15.72 ± 29.9 | -11.58 ± 30.0 | -1.60 ± 19.5 | -9.17 ± 21.5 | -1.63 ± 20.2 | 0.19 ± 32.6 |
| Change at Day 42: CD4 | -25.65 ± 30.3 | -19.27 ± 29.2 | -11.42 ± 30.0 | -4.08 ± 17.5 | -12.27 ± 24.6 | -3.81 ± 12.0 | 0.96 ± 35.7 |
| Change at Day 42: CD8 | -12.74 ± 29.1 | -10.04 ± 37.2 | -12.93 ± 33.9 | -5.60 ± 19.8 | -3.24 ± 17.6 | 4.19 ± 31.4 | 3.57 ± 33.5 |
| Change at Day 42: CD16/56 | -9.01 ± 25.4 | 21.15 ± 70.8 | -2.32 ± 27.9 | 2.87 ± 76.1 | 24.08 ± 35.8 | -4.54 ± 37.4 | 19.90 ± 41.5 |
| Change at Day 42: CD19 | -31.86 ± 30.9 | 6.43 ± 33.6 | -9.39 ± 29.2 | -10.22 ± 27.3 | -20.20 ± 30.0 | -8.30 ± 16.8 | -3.93 ± 52.5 |
The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (\<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, \>= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy.
| ng/mL | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline: Stimulated ATP(n=2,5,10,9,9,7,13) | 222.75 ± 157.3 | 205.40 ± 143.1 | 429.00 ± 115.3 | 406.11 ± 171.6 | 210.56 ± 104.1 | 252.50 ± 146.3 | 301.88 ± 152.9 |
| Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13) | 11.50 ± 9.9 | 10.60 ± 3.2 | 16.30 ± 6.6 | 16.44 ± 10.2 | 14.11 ± 8.3 | 7.14 ± 5.9 | 16.00 ± 12.4 |
| Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13) | 92.75 ± 120.6 | 95.80 ± 135.0 | 155.11 ± 168.0 | 90.11 ± 125.9 | 118.78 ± 88.2 | 61.21 ± 124.7 | 26.81 ± 66.6 |
| Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13) | 9.50 ± 2.8 | 5.60 ± 11.4 | 0.44 ± 8.9 | 0.33 ± 10.6 | 1.67 ± 15.4 | 0.29 ± 13.1 | 1.46 ± 11.2 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/cubic millimeter (cells/mm^3) | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Baseline (n=5,5,10,9,9,8,13) | 124.00 ± 30.6 | 94.00 ± 36.9 | 81.50 ± 20.1 | 95.22 ± 14.3 | 80.56 ± 24.4 | 79.75 ± 25.8 | 100.69 ± 46.2 |
| Change at Day 2 (n=5,5,9,9,8,8,12) | -6.60 ± 21.3 | -2.00 ± 13.7 | 20.00 ± 16.1 | -17.67 ± 24.2 | -10.88 ± 19.7 | -3.75 ± 11.1 | -7.25 ± 28.8 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/mm^3 | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Day 4 | -14.00 ± 17.2 | -7.60 ± 16.5 | 17.33 ± 26.6 | -48.44 ± 13.3 | -14.67 ± 16.4 | -20.00 ± 14.9 | -20.85 ± 41.2 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/mm^3 | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Day 7 | -3.40 ± 18.7 | 6.40 ± 15.9 | 17.11 ± 26.5 | -14.44 ± 13.6 | 3.22 ± 20.6 | -30.38 ± 13.8 | -1.38 ± 31.1 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/mm^3 | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Day 10 | -16.40 ± 29.5 | -14.00 ± 18.3 | 16.00 ± 25.9 | -18.22 ± 15.9 | 6.56 ± 17.5 | -29.50 ± 21.5 | -3.42 ± 38.8 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/mm^3 | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Day 15 | -24.00 ± 25.3 | -11.40 ± 17.4 | -8.56 ± 11.9 | -42.22 ± 16.9 | 24.11 ± 16.8 | -31.57 ± 25.9 | -17.92 ± 28.4 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/mm^3 | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Day 21 | -13.40 ± 30.6 | 17.60 ± 11.5 | 44.22 ± 27.1 | 5.44 ± 14.4 | 40.25 ± 15.6 | -9.17 ± 23.9 | 12.54 ± 40.2 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/mm^3 | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Day 28 | -16.20 ± 8.2 | 47.60 ± 14.8 | 49.56 ± 24.0 | 23.89 ± 23.5 | 21.75 ± 13.6 | 56.00 ± 24.1 | -2.85 ± 32.5 |
Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.
| 1000 cells/mm^3 | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Reticulocyte Count at Day 42 | -4.60 ± 12.6 | -7.00 ± 35.9 | 34.56 ± 30.0 | -3.67 ± 12.5 | -2.33 ± 21.9 | 22.50 ± 31.7 | -18.00 ± 26.7 |
No measurements were reported for this outcome.
EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured.
| ng*hr/mL | All CP-690,550 Treated Participants |
|---|---|
| Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50) | 2696 |
Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity.
| participants | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Erythema: 0 | 1 | 0 | 0 | 2 | 2 | 4 | 0 |
| Erythema: 1 | 3 | 4 | 8 | 7 | 4 | 4 | 4 |
| Erythema: 2 | 1 | 1 | 1 | 0 | 3 | 0 | 9 |
| Erythema: 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythema: 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Induration: 0 | 0 | 1 | 3 | 4 | 1 | 6 | 1 |
| Induration: 1 | 2 | 3 | 5 | 3 | 6 | 0 | 2 |
| Induration: 2 | 2 | 1 | 1 | 2 | 2 | 2 | 9 |
| Induration: 3 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Induration: 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Scaling: 0 | 0 | 1 | 1 | 0 | 2 | 5 | 0 |
| Scaling: 1 | 3 | 2 | 6 | 7 | 3 | 2 | 8 |
| Scaling: 2 | 2 | 2 | 2 | 2 | 4 | 1 | 4 |
| Scaling: 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Scaling: 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis).
| participants | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| PGA:1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PGA:2 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| PGA:3 | 3 | 1 | 3 | 2 | 0 | 0 | 5 |
| PGA:4 | 0 | 3 | 2 | 1 | 4 | 2 | 2 |
| PGA:5 | 1 | 0 | 2 | 4 | 3 | 0 | 5 |
| PGA:6 | 0 | 1 | 2 | 2 | 0 | 4 | 1 |
| PGA:7 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC.
| relative expression unit (REU) | CP-690,550 5 mg (Cohort 1) | CP-690,550 30 mg (Cohort 4) | Placebo |
|---|---|---|---|
| BCL-2 | 0.47 ± 0.09 | 0.36 ± 0.14 | 2.29 ± NA |
| BAX | 1.16 ± 0.21 | 0.83 ± 0.28 | 0.68 ± NA |
| CD25 | 7.34 ± 2.33 | 1.05 ± 0.27 | 0.16 ± NA |
| CXCL10 | 15.03 ± 5.75 | 0.44 ± 0.45 | 0.04 ± NA |
| Granzyme B | 42.71 ± 18.54 | 1.20 ± 0.07 | 0.03 ± NA |
| IL-2 | 0.98 ± 0.16 | 0.87 ± 0.02 | 0.75 ± NA |
| IL-8 | 556.12 ± 754.91 | 14.66 ± NA | 0.00 ± NA |
| INOS | 77.79 ± 40.10 | 0.97 ± 0.08 | 0.02 ± NA |
| INF-gamma | 2.26 ± 1.49 | 0.90 ± 0.09 | 0.22 ± NA |
| IL-15 | 0.51 ± 0.01 | 0.70 ± 0.06 | 0.86 ± NA |
| IL-7 | 0.85 ± 0.11 | 1.26 ± 0.51 | 1.19 ± NA |
| K-16 | 69.04 ± 7.60 | 5.18 ± 2.63 | 0.04 ± NA |
| PCNA | 2.09 ± 0.77 | 1.15 ± 0.06 | 0.41 ± NA |
| Perforin | 2.80 ± 2.56 | 0.65 ± 0.17 | 0.23 ± NA |
| TNF-FasL | 0.95 ± 0.24 | 1.24 ± 0.86 | 0.64 ± NA |
Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo.
| cells/microliter (cells/μL) | CP-690,550 5 mg (Cohort 1) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | Placebo |
|---|---|---|---|---|
| Baseline: CD3 epidermal (n=1,1,4,2) | 115.00 ± NA | 108.00 ± NA | 122.50 ± 50.8 | 124.50 ± 55.9 |
| Baseline: CD3 dermal (n=1,1,4,2) | 189.00 ± NA | 135.00 ± NA | 130.00 ± 81.3 | 196.00 ± 99.0 |
| Baseline: CD8 epidermal (n=1,1,4,2) | 66.00 ± NA | 55.00 ± NA | 108.50 ± 40.9 | 71.50 ± 19.1 |
| Baseline: CD8 dermal (n=1,1,4,2) | 23.00 ± NA | 53.00 ± NA | 123.75 ± 103.6 | 74.00 ± 70.7 |
| Baseline: CD83 epidermal (n=1,1,4,2) | 13.00 ± NA | 44.00 ± NA | 17.00 ± 12.1 | 1.50 ± 0.7 |
| Baseline: CD83 dermal (n=1,1,4,2) | 11.00 ± NA | 78.00 ± NA | 18.00 ± 7.3 | 3.00 ± 0.0 |
| Baseline: Absolute CD16/56 (n=0,0,0,0) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 14: CD3 epidermal (n=1,1,4,2) | 148.00 ± NA | 96.00 ± NA | 82.25 ± 121.0 | 97.00 ± 41.0 |
| Day 14: CD3 dermal (n=1,1,4,2) | 120.00 ± NA | 114.00 ± NA | 95.25 ± 59.4 | 92.00 ± 53.7 |
| Day 14: CD8 epidermal (n=1,1,4,2) | 85.00 ± NA | 56.00 ± NA | 51.50 ± 50.8 | 41.50 ± 34.6 |
| Day 14: CD8 dermal (n=1,1,4,2) | 27.00 ± NA | 42.00 ± NA | 90.50 ± 54.4 | 25.00 ± 9.9 |
| Day 14: CD83 epidermal (n=1,1,4,2) | 42.00 ± NA | 11.00 ± NA | 1.25 ± 1.5 | 7.00 ± 9.9 |
| Day 14: CD83 dermal (n=1,1,4,2) | 26.00 ± NA | 17.00 ± NA | 3.25 ± 2.2 | 9.50 ± 9.2 |
| Day 14: Absolute CD16/56 (n=0,0,0,0) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes.
| participants | CP-690,550 5 mg (Cohort 1) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | Placebo |
|---|---|---|---|---|
| Baseline | 1 | 1 | 4 | 2 |
| Day 14 | 1 | 1 | 4 | 2 |
Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes.
No measurements were reported for this outcome.
Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 \[SF5\]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA).
| relative expression unit (REU) | CP-690,550 5 mg (Cohort 1) | CP-690,550 30 mg (Cohort 4) | Placebo |
|---|---|---|---|
| Granzyme B (n=9,9,6) | 0.69 ± 0.33 | 0.99 ± 0.58 | 1.58 ± 1.13 |
| IFN-gamma (n=9,9,6) | 2.06 ± 1.58 | 1.16 ± 0.59 | 1.46 ± 0.86 |
| TNF-SF5 (n=9,9,6) | 1.79 ± 1.14 | 1.29 ± 0.48 | 1.24 ± 0.38 |
| TNF-FasL (n=9,9,6) | 0.99 ± 0.37 | 1.09 ± 0.53 | 1.27 ± 0.83 |
| BCL2 (n=9,9,6) | 0.71 ± 0.40 | 0.90 ± 0.30 | 1.01 ± 0.22 |
| BAX (n=9,9,6) | 1.10 ± 0.32 | 0.98 ± 0.25 | 0.97 ± 0.22 |
| iNOS (n=2,1,1) | 77.79 ± 40.10 | 0.97 ± 0.08 | 0.02 ± NA |
| CD 25 (n=9,9,6) | 1.19 ± 0.50 | 1.02 ± 0.29 | 1.01 ± 0.24 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 5 mg (Cohort 1) | — | 0/5 (0%) | 0/5 (0%) |
| CP-690,550 10 mg (Cohort 2) | — | 1/5 (20%) | 1/5 (20%) |
| CP-690,550 20 mg (Cohort 3) | — | 0/10 (0%) | 3/10 (30%) |
| CP-690,550 30 mg (Cohort 4) | — | 0/9 (0%) | 1/9 (11.1%) |
| CP-690,550 60 mg (Cohort 5) | — | 0/9 (0%) | 2/9 (22.2%) |
| CP-690,550 50 mg (Cohort 6) | — | 0/8 (0%) | 2/8 (25%) |
| Placebo | — | 0/13 (0%) | 2/13 (15.4%) |
| Event | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/5 | 1/5 | 0/10 | 0/9 | 0/9 | 0/8 | 0/13 |
| Event | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/5 | 1/5 | 0/10 | 0/9 | 0/9 | 2/8 | 0/13 |
| HeadacheGeneral disorders | 0/5 | 1/5 | 0/10 | 0/9 | 1/9 | 1/8 | 2/13 |
| Lab test abnormalGeneral disorders | 0/5 | 0/5 | 0/10 | 1/9 | 0/9 | 0/8 | 0/13 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/5 | 0/5 | 0/10 | 0/9 | 1/9 | 0/8 | 0/13 |
| Peripheral edemaMetabolism and nutrition disorders | 0/5 | 0/5 | 1/10 | 0/9 | 0/9 | 0/8 | 0/13 |
| SGOT increasedMetabolism and nutrition disorders | 0/5 | 0/5 | 1/10 | 0/9 | 0/9 | 0/8 | 0/13 |
| SGPT increasedMetabolism and nutrition disorders | 0/5 | 0/5 | 1/10 | 0/9 | 0/9 | 0/8 | 0/13 |
| ArthrosisMusculoskeletal and connective tissue disorders | 0/5 | 0/5 | 1/10 | 0/9 | 0/9 | 0/8 | 0/13 |
| InsomniaNervous system disorders | 0/5 | 0/5 | 0/10 | 0/9 | 0/9 | 0/8 | 1/13 |
| Age Continuous(years) | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 40.2 ± 12.8 | 43.8 ± 7.4 | 39.6 ± 11.1 | 44.6 ± 11.1 | 46.9 ± 10.2 | 47.1 ± 9.7 | 44.4 ± 10.4 | 43.9 ± 10.3 |
| Sex: Female, Male(Participants) | CP-690,550 5 mg (Cohort 1) | CP-690,550 10 mg (Cohort 2) | CP-690,550 20 mg (Cohort 3) | CP-690,550 30 mg (Cohort 4) | CP-690,550 60 mg (Cohort 5) | CP-690,550 50 mg (Cohort 6) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 3 | 1 | 4 | 4 | 5 | 22 |
| Male | 2 | 3 | 7 | 8 | 5 | 4 | 8 | 37 |
The record gives a start of Nov 2002, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 8 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib